DXB Media thread., page-55

A great deal of patience is required here and DXB investment could be life changing investment, however this will take time. Listening to Nina's recent interview the data they are receiving is very encouraging so I trust that clinical efficacy result from mid-March report will have statistical significance. This entails following:

• No CR required for remainder of the trial for Phase 2 & 3 of ACTION-3 as DXB has potential to receive up to $232M from Advanz alone
• Commercial agreement with for 2 geographical regions (US and China) will be follow. Japan and South America in the pipeline other geographical region what I can think of. With success of mid-March result, I consider US and China agreements could be twice the $ value from Advanz.
• The Chinese Clinical sites on mainland China are already intended for Part 2 of the FSGS ACTION3 Phase 3 clinical trial and addition sites recruiting in 11 other countries
• The fast track (IND aka emergency) approval DXB200 from FDA and similar judications could be imminent as there is no alternative medication available FSGS.

I'm trusting my investment and DXB could be another beast in next 1-2 years but I suggest option holders not to throw your cheap shares and undervalue DXB as success may take time and worth wait.

DYOR before any buy or sell